KDR and adrenal cortex carcinoma: Among systemic therapies, studies demonstrating promising clinical benefits with VEGFR TKIs, especially lenvatinib (though also axitinib and more recently rivoceranib), have solidified the role of these agents in the R/M ACC setting.